التفاصيل البيبلوغرافية
| العنوان: |
Perceptions of Diabetes Technology Use in Cystic Fibrosis-Related Diabetes Management. |
| المؤلفون: |
Marks, Brynn E.1,2 (AUTHOR) bmarks@childrensnational.org, Kilberg, Marissa J.3,4 (AUTHOR), Aliaj, Enid5 (AUTHOR), Fredkin, Kelsey5 (AUTHOR), Hudson, Jessica5 (AUTHOR), Riva, Dara5 (AUTHOR), Román, Christina5 (AUTHOR), Kelly, Andrea3,4 (AUTHOR), Putman, Melissa S.6,7,8 (AUTHOR), Kilberg, Marissa9,10 (AUTHOR) |
| المصدر: |
Diabetes Technology & Therapeutics. Nov2021, Vol. 23 Issue 11, p753-759. 7p. |
| مصطلحات موضوعية: |
*GLYCEMIC control, *TYPE 1 diabetes, *HYPERGLYCEMIA, *INSULIN pumps, *DIABETES, *DIAGNOSIS, *QUALITY of life, *INSULIN therapy, *RESEARCH, *BLOOD sugar monitoring, *EVALUATION research, *CYSTIC fibrosis, *COMPARATIVE studies, *TECHNOLOGY, *DISEASE complications |
| مستخلص: |
Background: Diabetes technologies are associated with improvements in glycemic control and health-related quality of life among people with type 1 diabetes (T1D). Use and perceptions of continuous glucose monitors (CGM) and insulin pumps within the cystic fibrosis (CF) community have not been well studied. Methods: A 30-item online survey addressing cystic fibrosis-related diabetes (CFRD) diagnosis, CGM and insulin pump use, and perceptions of diabetes technologies was sent to a CF community group, including people with CF (pwCF) and parents of children with CF (cwCF). Results: The response rate was 11% (n = 120; 83 pwCF, 35 cwCF). Sixty-one percent of pwCF and 34% of cwCF reported a diagnosis of CFRD. CGM use was reported by 75% (n = 47) of respondents with CFRD but was discontinued by 19% (n = 9), most commonly due to cost and increased worry about glycemia. Insulin pump therapy was reported by 29% (n = 18 of 62) of respondents with CFRD and was discontinued by 28% (n = 5), most commonly due to pain or skin irritation. Overall, 91% agreed or strongly agreed that CGM facilitated CFRD management. Eighty-one percent agreed with at least five of seven positive statements about CGM as compared with 22% for insulin pumps. Potential embarrassment over device wear, concerns about cost, and pain were commonly held negative perceptions of both technologies. Conclusions: As compared with T1D and despite perceived benefits, rates of sustained diabetes technology use are low in the CFRD community. Better insurance coverage to mitigate cost, better patient education, and confirmation that these technologies improve health and patient-reported outcomes may increase uptake. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
